In a B16 melanoma model expressing HER2, treatment with a CD1d-antibody fusion protein targeting HER2 increased iNKT cell inflammatory cytokine production and targeted lysis of tumor cells, decreasing metastasis formation [114]. The gene discussed is ERBB2; the disease is neoplasm.